Form 4: Madrigal Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
A Madrigal Pharmaceuticals executive sold 442 shares of common stock at $273.41 per share to cover tax obligations related to vesting restricted stock units.
Summary
- Robert E. Waltermire, Senior VP and Chief Pharma Development at Madrigal Pharmaceuticals, sold 442 shares of common stock.
- The sale occurred on January 17, 2025, at a price of $273.41 per share.
- The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- The sale was automatic and not at the discretion of Mr. Waltermire.
- Following the transaction, Mr. Waltermire directly owns 5,058 shares of Madrigal Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment towards the company's performance or future prospects.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, which is common in publicly traded companies. It does not indicate any specific trend or issue within the pharmaceutical industry.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a standard practice across publicly traded companies, including those in the pharmaceutical sector.
- Similar transactions are regularly reported by executives at companies like Regeneron, Gilead, and Vertex, often following the vesting of stock options or restricted stock units.
- The size of the transaction is relatively small compared to the overall market capitalization of Madrigal Pharmaceuticals and is not unusual for an executive at this level.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The sale does not affect the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of the stock sale transaction. |
Keywords
Madrigal Pharmaceuticals, stock sale, insider trading, Form 4, executive compensation, tax obligations, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.